Dossier assessment

Deucravacitinib (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Adults with active psoriatic arthritis

Result of dossier assessment:

Patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy: added benefit not proven
Patients who have had an inadequate response or who have been intolerant to a prior therapy with biologic DMARDs: added benefit not proven

Project no.: A26-66
Commission: Commission awarded on 01.06.2026 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Skin and hair
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI: https://doi.org/10.60584/A26-66

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.